OXPHOS
Inhibitory Selectivity
OXPHOS Products
| Catalog No. | Information | Product Use Citations | Product Validations |
|---|---|---|---|
| S2987New |
4-Methyl-2-oxovaleric acid4-Methyl-2-oxovaleric acid (Ketoleucine, 4-MOV, KIC, 4-Methyl-2-oxopentanoic acid, alpha-Ketoisocaproic acid, alpha-ketoisocaproate, 2-Oxoisohexanoate) is released by Astrocytes to neurons and can be reaminated by aminotransferase to leucine. 4-Methyl-2-oxovaleric acid reduces the rate of protein degradation in skeletal muscle. 4-Methyl-2-oxovaleric acid acts as an uncoupler of oxidative phosphorylation (OXPHOS) and as a metabolic inhibitor possibly through its inhibitory effect on alpha-ketoglutarate dehydrogenase (oxoglutarate dehydrogenase complex, OGDC) activity. |
||
| S8731 |
IACS-010759 (IACS-10759)IACS-010759 (IACS-10759) is a potent and selective oxidative phosphorylation inhibitor (IC50 < 10 nM) that blocks cellular respiration through inhibition of complex I. |
||
| S8943 |
VLX600VLX600 is a novel iron-chelating inhibitor of oxidative phosphorylation (OXPHOS), potentiates the effect of radiation in tumor spheroids in a synergistic manner. VLX600 shows enhanced cytotoxic activity under conditions of nutrient starvation. VLX600 induces autophagy and mitochondrial inhibition with antitumor activity. |
||
| S0096 |
S-GboxinS-Gboxin, a functional analogue of Gboxin, is an oxidative phosphorylation (OXPHOS) inhibitor which inhibits growth of mouse and human glioblastoma (GBM) with IC50 of 470 nM. |
||
| S9604 |
IM156IM156 (HL156A), a metformin derivative, is a potent activator of AMPK that increases AMPK phosphorylation. IM156 blocks oxidative phosphorylation (OXPHOS) through the inhibition of complex I and increases apoptosis. IM156 ameliorates various types of fibrosis and inhibits tumors. |
||
| S8276 |
FCCPFCCP (Trifluoromethoxy carbonylcyanide phenylhydrazone, Carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone) is a potent uncoupler of oxidative phosphorylation in mitochondria that disrupts ATP synthesis by transporting protons across cell membranes. |
The changes in 10-N-nonylacridineorange (NAO) fluorescence indicated the cardiolipin (CL) oxidation. In normal cells, NAO could interact with nonoxidized cardiolipin and produces a characteristic green fluorescence. However, after cardiolipin is oxidized, NAO cannot bind to it. F-H, The changes in MDA, GSH, and SOD levels. I and J, The cytoplasmic [Ca2+] map via confocal microscopy by Fluo-2. Fluorescence intensity of Fluo-2 was measured by excitation wavelengths of 340 nm and emission wavelengths of 500 nm. Data (F/F0) were obtained by dividing fluorescence intensity (F) by (F0) at the resting level (t = 0), which was normalized to normal groups. Data are shown as means ± SEM. *P < .05 vs normal group; #P < .05 vs PA group, @P < .05 vs PA + siRNA-NR4A1 or PA + melatonin groups
|
|
| S8828 |
GboxinGboxin is an inhibitor of oxidative phosphorylation in cancer cells. Gboxin inhibits the activity of F0F1 ATP synthase. It specifically inhibits the growth of primary mouse and human glioblastoma cells but not that of mouse embryonic fibroblasts or neonatal astrocytes. |
| Catalog No. | Information | Product Use Citations | Product Validations |
|---|---|---|---|
| S2987New |
4-Methyl-2-oxovaleric acid4-Methyl-2-oxovaleric acid (Ketoleucine, 4-MOV, KIC, 4-Methyl-2-oxopentanoic acid, alpha-Ketoisocaproic acid, alpha-ketoisocaproate, 2-Oxoisohexanoate) is released by Astrocytes to neurons and can be reaminated by aminotransferase to leucine. 4-Methyl-2-oxovaleric acid reduces the rate of protein degradation in skeletal muscle. 4-Methyl-2-oxovaleric acid acts as an uncoupler of oxidative phosphorylation (OXPHOS) and as a metabolic inhibitor possibly through its inhibitory effect on alpha-ketoglutarate dehydrogenase (oxoglutarate dehydrogenase complex, OGDC) activity. |
||
| S8731 |
IACS-010759 (IACS-10759)IACS-010759 (IACS-10759) is a potent and selective oxidative phosphorylation inhibitor (IC50 < 10 nM) that blocks cellular respiration through inhibition of complex I. |
||
| S8943 |
VLX600VLX600 is a novel iron-chelating inhibitor of oxidative phosphorylation (OXPHOS), potentiates the effect of radiation in tumor spheroids in a synergistic manner. VLX600 shows enhanced cytotoxic activity under conditions of nutrient starvation. VLX600 induces autophagy and mitochondrial inhibition with antitumor activity. |
||
| S0096 |
S-GboxinS-Gboxin, a functional analogue of Gboxin, is an oxidative phosphorylation (OXPHOS) inhibitor which inhibits growth of mouse and human glioblastoma (GBM) with IC50 of 470 nM. |
||
| S9604 |
IM156IM156 (HL156A), a metformin derivative, is a potent activator of AMPK that increases AMPK phosphorylation. IM156 blocks oxidative phosphorylation (OXPHOS) through the inhibition of complex I and increases apoptosis. IM156 ameliorates various types of fibrosis and inhibits tumors. |
||
| S8276 |
FCCPFCCP (Trifluoromethoxy carbonylcyanide phenylhydrazone, Carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone) is a potent uncoupler of oxidative phosphorylation in mitochondria that disrupts ATP synthesis by transporting protons across cell membranes. |
The changes in 10-N-nonylacridineorange (NAO) fluorescence indicated the cardiolipin (CL) oxidation. In normal cells, NAO could interact with nonoxidized cardiolipin and produces a characteristic green fluorescence. However, after cardiolipin is oxidized, NAO cannot bind to it. F-H, The changes in MDA, GSH, and SOD levels. I and J, The cytoplasmic [Ca2+] map via confocal microscopy by Fluo-2. Fluorescence intensity of Fluo-2 was measured by excitation wavelengths of 340 nm and emission wavelengths of 500 nm. Data (F/F0) were obtained by dividing fluorescence intensity (F) by (F0) at the resting level (t = 0), which was normalized to normal groups. Data are shown as means ± SEM. *P < .05 vs normal group; #P < .05 vs PA group, @P < .05 vs PA + siRNA-NR4A1 or PA + melatonin groups
|
|
| S8828 |
GboxinGboxin is an inhibitor of oxidative phosphorylation in cancer cells. Gboxin inhibits the activity of F0F1 ATP synthase. It specifically inhibits the growth of primary mouse and human glioblastoma cells but not that of mouse embryonic fibroblasts or neonatal astrocytes. |
